MK-677 (Ibutamoren) Pricing: April 2026

MK-677 (Ibutamoren) is an oral drug that activates the ghrelin receptor and triggers growth hormone (GH) release. It is popular in the peptide wellness community, but it is a small molecule rather than a peptide. That distinction shapes how people get it.

How it works: MK-677 activates the GHS-R1a receptor, and its half-life of about 24 hours means one dose a day sustains the GH and IGF-1 axis. Clinical studies show GH secretion rises up to about 97%, and IGF-1 returns to young-adult levels. Bedtime dosing is preferred, since a 25 mg dose at bedtime increased REM sleep 20% in young subjects and 50% in older subjects.

Common doses: 10 mg gives a modest response, 12.5 mg is a starting dose, and 25 mg daily is the most common therapeutic dose. Cycles usually run 8–16 weeks.

Forms: Oral capsules (10, 12.5, 15, or 25 mg) are most common, with liquid solution (25 mg/mL) and research powder also sold. There is no injectable form.

Regulatory status (April 2026): Not FDA-approved and not a controlled substance, but banned by WADA, the World Anti-Doping Agency, under category S2. The February 2026 RFK Jr. peptide reclassification left out MK-677 because it is not a peptide. Products sold over the counter as dietary supplements count as adulterated, and FDA issued recalls in September 2025 (iKids-Growth) and March 2026 (Agebox). The FDA Pharmacy Compounding Advisory Committee meets in July 2026 and may consider adding MK-677 to the 503A bulk list, which would let 503A pharmacies compound it from a doctor's prescription.

How people get it: Peptides like BPC-157 and GHK-Cu are widely prescribed by mainstream telehealth platforms (Maximus, Hone Health, Strut, AgelessRx), but MK-677 is not. Most real-world access runs through research chemical vendors, whose products are labeled "not for human consumption" and sold without a prescription. Insurance does not cover MK-677.